Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2+/HR− Trial
In: Clinical cancer research 29(4), 805-814 (2023). doi:10.1158/1078-0432.CCR-22-1587; (2023)
Online
unknown
Zugriff:
Clinical cancer research 29(4), 805-814 (2023). doi:10.1158/1078-0432.CCR-22-1587
Published by AACR, Philadelphia, Pa. [u.a.]
Titel: |
Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2+/HR− Trial
|
---|---|
Autor/in / Beteiligte Person: | Graeser, Monika ; Gluz, Oleg ; Biehl, Claudia ; Ulbrich-Gebauer, Daniel ; Christgen, Matthias ; Palatty, Jenci ; Kuemmel, Sherko ; Grischke, Eva-Maria ; Augustin, Doris ; Braun, Michael ; Potenberg, Jochem ; Wuerstlein, Rachel ; Krauss, Katja ; Schumacher, Claudia ; Forstbauer, Helmut ; Reimer, Toralf ; Stefek, Andrea ; Fischer, Hans Holger ; Pelz, Enrico ; Zu Eulenburg, Christine ; Kates, Ronald ; Ni, Hua ; Kolberg-Liedtke, Cornelia ; Feuerhake, Friedrich ; Kreipe, Hans Heinrich ; Nitz, Ulrike ; Harbeck, Nadia ; Investigators, WSG-ADAPT |
Link: | |
Quelle: | Clinical cancer research 29(4), 805-814 (2023). doi:10.1158/1078-0432.CCR-22-1587; (2023) |
Veröffentlichung: | RWTH Aachen University, 2023 |
Medientyp: | unknown |
ISSN: | 1078-0432 (print) |
DOI: | 10.18154/rwth-conv-250791 |
Schlagwort: |
|
Sonstiges: |
|